Keyphrases
Melanoma Brain Metastases
100%
Brain Distribution
100%
Active Efflux
100%
Melanoma Treatment
100%
LY3009120
100%
P-glycoprotein (P-gp)
75%
Breast Cancer Resistance Protein
75%
Blood-brain Barrier
50%
Amino
50%
Methyl
50%
In Vivo Efficacy
50%
Mitogen-activated Protein Kinase
50%
Chloro
50%
Fluoro
50%
Phenylurea
50%
BRAF Inhibitor (BRAFi)
50%
Paradoxical Activation
50%
Transgenic Mice
25%
Pyrido
25%
Ethyl
25%
In Vitro Study
25%
Melanoma
25%
Acquired Resistance
25%
ABCG2
25%
Melanoma Cells
25%
Patient-derived
25%
BRAF-mutant Melanoma
25%
Non-specific Binding
25%
Carbonyl
25%
Madin-Darby Canine Kidney (MDCK) Cells
25%
Site of Action
25%
Tert-butyl
25%
Phenyl
25%
Trifluoromethyl
25%
ATP Binding Cassette Subfamily B Member 1 (ABCB1)
25%
Targeted Inhibition
25%
Efficacy Outcomes
25%
Improved Efficacy
25%
Pyridinyl
25%
Molecular Targeted Agents
25%
Secondary Malignancy
25%
Thiazolyl
25%
Pyrazol
25%
Efflux Mechanism
25%
Drug Potency
25%
MEK Inhibitor (MEKi)
25%
Medicine and Dentistry
Breast Cancer Resistance Protein
100%
Brain Metastasis
100%
Effusion
100%
ABC Transporter Subfamily B
100%
Melanoma
100%
In Vitro
66%
Blood Brain Barrier
66%
Mitogen-Activated Protein Kinase
66%
Transgenic Mouse
33%
Cancer
33%
MEK Inhibitor
33%
Kinase Signaling
33%
Melanoma Cell Line
33%
Phenazone
33%
Drug Potency
33%
Biochemistry, Genetics and Molecular Biology
ABCG2
100%
P-Glycoprotein
100%
Quantitative Technique
66%
Blood Brain Barrier
66%
Mitogen-Activated Protein Kinase
66%
Isoform
33%
In Vivo Study
33%
In Vitro Study
33%
Transgenic Mouse
33%
Drug Potency
33%
MEK Inhibitor
33%
Blood Plasma
33%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Effusion
100%
Brain Metastasis
100%
P-Glycoprotein
75%
ABCG2
75%
Mitogen Activated Protein Kinase
50%
Blood-Brain Barrier
50%
Transgenic Mouse
25%
Mitogen Activated Protein Kinase Kinase Inhibitor
25%
Phenazone
25%